Epinephrine-Induced QT Interval Prolongation: A Gene-Specific Paradoxical Response in Congenital Long QT Syndrome
|
|
- Rudolph Dixon
- 8 years ago
- Views:
Transcription
1 Mayo Clin Proc, May 2002, Vol 77 Infusion QT Stress Testing in LQTS 413 Original rticle -Induced QT Interval Prolongation: Gene-Specific Paradoxical Response in Congenital Long QT Syndrome MICHEL J. CKERMN, MD, PHD; NNT KHOSITSETH, MD; DVID J. TESTER, S; JOSEPH. HEJLIK, RN; WIN-KUNG SHEN, MD; ND CO-URN J. PORTER, MD Objective: To determine the effect of epinephrine on the QT interval in patients with genotyped long QT syndrome (LQTS). Patients and Methods: etween May 1999 and pril 2001, 37 patients (24 females) with genotyped LQTS (19 LQT1, 15 LQT2, 3 LQT3, mean age, 27 years; range, years) from 21 different kindreds and 27 (16 females) controls (mean age, 31 years; range, years) were studied at baseline and during gradually increasing doses of intravenous epinephrine infusion (0.05, 0.1, 0.2, and 0.3 µg kg 1 min 1 ). The 12-lead electrocardiogram was monitored continuously, and heart rate, QT, and corrected QT interval (QTc) were measured during each study stage. Results: There was no significant difference in resting heart rate or chronotropic response to epinephrine between LQTS patients and controls. The mean ± SD baseline QTc was greater in LQTS patients (500±68 ms) than in controls (436±19 ms, P<.001). However, 9 (47%) of 19 KVLQT1-genotyped LQT1 patients had a nondiagnostic resting QTc (<460 milliseconds), whereas 11 (41%) of 27 controls had a resting QTc higher than 440 milliseconds. During epinephrine infusion, every LQT1 patient manifested prolongation of the QT interval (paradoxical response), whereas healthy controls and patients with ei- ther LQT2 or LQT3 tended to have shortened QT intervals (P<.001). The maximum mean ± SD change in QT ( QT [epinephrine QT minus baseline QT]) was 5±47 ms (controls), +94±31 ms (LQT1), and 87±67 ms (LQT2 and LQT3 patients). Of 27 controls, 6 had lengthening of their QT intervals ( QT >30 milliseconds) during high-dose epinephrine. Low-dose epinephrine (0.05 µg kg 1 min 1 ) completely discriminated LQT1 patients ( QT, +82±34 ms) from controls ( QT, 7±13 ms; P<.001). triggered nonsustained ventricular tachycardia occurred in 2 patients with LQTS and in 1 control. Conclusions: -induced prolongation of the QT interval appears pathognomonic for LQT1. Lowdose epinephrine infusion distinguishes controls from patients with concealed LQT1 manifesting an equivocal QTc at rest. Thus, epinephrine provocation may help unmask some patients with concealed LQTS and strategically direct molecular genetic testing. Mayo Clin Proc. 2002;77: ECG = electrocardiogram; LQTS = long QT syndrome; NSVT = nonsustained ventricular tachycardia; PVCs = premature ventricular contractions; QTc = corrected QT interval; TW = T-wave alternans The congenital long QT syndrome (LQTS) comprises the first genetically defined type of arrhythmia to be understood at the molecular level as a primary cardiac channelopathy. 1-3 To date, 6 LQTS loci; 5 LQTS genes KVLQT1 (KCNQ1 [LQT1]), HERG (KCNH2 [LQT2]), SCN5 (LQT3), KCNE1 (mink [LQT5]), and KCNE2 From the Division of Cardiovascular Diseases and Internal Medicine (M.J.., D.J.T., J..H., W.-K.S.), Division of Pediatric Cardiology (M.J..,.K., C.J.P.), and Department of Molecular Pharmacology and Experimental Therapeutics (M.J..), Mayo Clinic, Rochester, Minn. Dr ckerman was supported by a Doris Duke Clinical Scientist Development ward from the Doris Duke Charitable Foundation and a Mayo Foundation clinical research award. Presented in part at the Society for Pediatric Research annual meeting, oston, Mass, May 12-16, 2000, and at the North merican Society of Pacing and Electrophysiology annual meeting, oston, Mass, May 2-5, ddress reprint requests and correspondence to Michael J. ckerman, MD, PhD, Division of Pediatric Cardiology, Mayo Clinic, 200 First St SW, Rochester, MN ( (MiRP1 [LQT6]) 4-8 ; and more than 200 LQTS-causing mutations 9 have been identified and compiled in an LQTS database ( The LQTS subtype 1 (LQT1) is secondary to defects in the cardiac potassium channel encoded by KVLQT1, LQTS subtype 2 (LQT2) is secondary to defects in the cardiac potassium channel gene encoded by HERG, and LQTS subtype 3 (LQT3) is secondary to defects in the cardiac sodium channel gene encoded by SCN5. Unlike the F508del- CFTR mutation in cystic fibrosis that accounts for approximately 70% of cystic fibrosis, there are no hot spots in the LQTS genes. 2 For editorial comment, see page 405. Clinically, LQTS affects approximately 1 in 5000 persons and can cause syncope, seizures, and sudden death. Such events occur when the cardiac rhythm degenerates into the hallmark tachyarrhythmia of LQTS termed torsades de pointes. Certain triggers such as intense adrenergic or auditory stimulation appear particularly arrhyth- Mayo Clin Proc. 2002;77: Mayo Foundation for Medical Education and Research
2 414 Infusion QT Stress Testing in LQTS Mayo Clin Proc, May 2002, Vol 77 Table 1. Demographics for Controls and Patients With Long QT Syndrome* Control LQT1 LQT2/3 Sex (F/M) 16/11 13/6 11/7 ge (y) 31.3± ± ±12.1 aseline QT interval (ms) 418±28 449±28 535±66 aseline corrected QT interval (QTc, ms) 436±19 463±29 539±74 aseline heart rate (beats/min) 66±10 65±9 61±8 Peak heart rate with epinephrine (beats/min) 90±16 84±15 90±14 Change in heart rate (beats/min) 24±12 19±15 29±11 *ll values are ± SD unless stated otherwise. Patients with LQT2 and LQT3 were combined for analysis. mogenic in LQTS. 10,11 One specific activity, swimming, has been shown to trigger symptoms in nearly 15% of children and young adults with LQTS and is virtually always due to mutations in KVLQT1 (LQT1). 11,12 Natural history studies suggest that 40% of patients remain asymptomatic, 50% have at least 1 cardiac event, and 5% to 10% may present with aborted cardiac arrest as a sentinel event. Thus, an accurate diagnosis of LQTS is of paramount importance. Pronounced prolongation of the corrected QT interval (QTc) (>460 milliseconds) on a resting 12-lead electrocardiogram (ECG) remains the cornerstone of the diagnosis of congenital LQTS. 3 However, even when such prolongation exists, computer diagnostic interpretation of the ECG may be erroneous. 13 Moreover, at least 25% of individuals with LQTS may manifest an ECG with an equivocal or borderline QTc (concealed LQTS). 14,15 New diagnostic modalities are needed for accurate identification of individuals who may harbor this potentially lethal arrhythmogenic substrate. Since many of the observed cardiac events are precipitated by sympathetic activation, exercise stress testing has been suggested to enhance the diagnostic accuracy in LQTS. 10,16,17 Swan et al 18 performed exercise tests in 45 genotyped LQT1 patients, 22 LQT2 patients, and 33 healthy genotype-negative relatives and showed that LQT1 patients had a diminished chronotropic response to exercise and an exaggerated prolongation of the QT interval during recovery from exercise. esides exercise testing, pharmacological provocation tests with use of catecholamines have been conducted in attempts to accurately identify the patient with LQTS. 19,20 Recently, we 21 described a family with concealed LQTS (normal screening ECGs) after an epinephrine provocation elicited significant prolongation of the QT interval during infusion of 0.1 µg kg 1 min 1. In contrast, a study involving 9 healthy volunteers showed that similar infusion rates of epinephrine slightly decreased the QT interval. 22 We speculated that epinephrine-mediated QT prolongation (a paradoxical response) might be an LQT1-specific response to epinephrine. 21 In fact, this abnormal epinephrine study finding fostered a successful molecular autopsy that confirmed a KVLQT1 mutation (LQT1) in the deceased person despite the sentinel event occurring during sleep. We tested our hypothesis by performing epinephrine infusion QT stress tests in 37 genotyped LQTS patients, including 19 with KVLQT1-based LQT1, and 27 age- and sex-matched healthy controls. PTIENTS ND METHODS Study Population etween May 1999 and pril 2001, 64 persons, including 19 (13 female) LQT1 patients (age, 26.7±10.4 years, range, years), 18 (11 female) LQT2/3 patients (15 LQT2 and 3 LQT3; age, 27.5±12.1 years, range, years), and 27 age- and sex-matched healthy controls (16 females; age, 31.3±11.4 years, range, years), underwent an epinephrine infusion QT stress test. Patients with LQTS were genotyped after written informed consent, and the epinephrine studies were conducted as part of their clinical evaluation. Controls underwent epinephrine provocation approved by the Mayo Foundation Institutional Review oard after written informed consent. Controls either (1) had no personal history of syncope, family history of sudden cardiac death, or ECG evidence of diagnostic QT interval prolongation on their baseline 12-lead ECG (n=23) or (2) were genotype-negative LQTS family members (n=4). Of 19 patients with LQT1, 11 were genotyped successfully before the epinephrine study, whereas the specific KVLQT1 mutation was established after the epinephrine study in the remaining 8 LQT1 patients. Similarly, 10 of the 18 LQT2/3 patients were already genotyped as 9 HERG mutations and 1 distinct SCN5 mutation. Patient demographics are shown in Table 1, and the spectrum of mutations represented in this study is depicted in Figure 1. Only 2 LQTS patients (LQT2) were taking β-blockers at the time of their epinephrine QT stress test. The remaining patients had not yet begun β-blocker therapy because the epinephrine challenge was part of the initial evaluation or the patient was noncompliant, had chosen implantable cardioverter-defibrillator device monotherapy, or had testing conducted after monitored β-blocker washout.
3 Mayo Clin Proc, May 2002, Vol 77 Infusion QT Stress Testing in LQTS 415 Figure 1. Spectrum of channel mutations in the cohort of patients with long QT syndrome (LQTS). Schematic of a prolonged cardiac action potential duration from a ventricular myocyte is shown with the linear topologies of the cardiac channels responsible for LQT1 (KVLQT1), LQT2 (HERG), and LQT3 (SCN5). There were 19 LQT1 patients studied who had 11 distinct KVLQT1 mutations, 15 LQT2 patients who had 9 distinct HERG mutations, and 3 LQT3 patients who had the same missense mutation. Circles denote the missense mutations, and squares indicate insertion/deletion mutations. The lightning bolt in KVLQT1 represents a splicing mutation. Not shown in KVLQT1 is the splicing mutation denoted SP/639+5 g>a. Infusion QT Stress Test These studies were performed in the clinical electrophysiology laboratory with a physician and nurse present. ll LQTS patients and controls were connected to a bedside cardioverter-defibrillator device at the start of study and were monitored by continuous 12-lead ECG and continuous blood pressure monitoring. fter baseline evaluation while supine, an infusion of epinephrine was initiated at 0.05 µg kg 1 min 1, and repolarization measurements (QT, R-R, and QTc) were determined after 10 minutes of low-dose epinephrine. The QTc was calculated by the azett formula: the absolute QT interval divided by the square root of the preceding R-R interval. Next, the epinephrine infusion was increased sequentially to 0.1, 0.2, and 0.3 µg kg 1 min 1 with measurements made after 5 minutes at each subsequent dose and, finally, at 10 minutes into the recovery period. The total duration of epinephrine infusion was 25 minutes, and the overall study was completed in 45 minutes. The interval measurements were obtained from lead II, typically by using digital calipers and a recorded tracing speed of 50 mm/s. t least 4 beats were averaged for each study stage. The change in QT ( QT) and the change in QTc ( QTc) were calculated by the difference between the maximal or minimal QT and QTc during epinephrine infusion compared to baseline. Criteria to discontinue epinephrine infusion included systolic blood pressure 200 mm Hg or higher, nonsustained ventricular tachycardia (NSVT) or polymorphic VT, increasing premature ventricular contractions (PVCs) (>10 PVCs/min), T-wave alternans (TW), or patients intolerance due to headache and/or nausea. Statistical nalysis ll continuous variables were reported as mean ± SD. One-way analysis of variance followed by Tukey-Kramer honestly significant difference test was used to compare
4 416 Infusion QT Stress Testing in LQTS Mayo Clin Proc, May 2002, Vol 77 Figure 2. Genotype and baseline corrected QT interval (QTc) in patients with long QT syndrome (LQTS). Mean values, standard deviation bar, and individual data points for the resting baseline QTc are indicated for controls, LQT1 patients, and LQT2/3 patients. Patients with LQTS had a greater QTc than controls (P<.001), and patients with LQT2/3 had a longer QTc than those with LQT1 (P<.002). measurements among the 3 groups before and after epinephrine infusion and to compare each parameter among LQT1 and LQT2/3 patients and controls. LQT2 (n=15) and LQT3 (n=3) patients were combined for analysis in order to compare LQTS patients with a defective KVLQT1-mediated cardiac potassium current (I Ks [LQT1]) with those having an intact I Ks (LQT2/3). paired Student t test was used to compare parameters between the 2 groups. P<.05 was considered statistically significant. RESULTS s expected, baseline QT intervals and calculated QTc were significantly longer in LQTS patients compared with controls (P<.001): QT, 490±66 ms (LQTS) vs 418±28 ms (controls) and QTc, 500±68 ms (LQTS) vs 436±19 ms (controls). In addition, baseline QT intervals and QTc in LQT2/3 patients were significantly longer than in LQT1 patients (P<.002): QT, 535±66 ms (LQT2/3) vs 449±28 ms (LQT1) and QTc, 539±74 ms (LQT2/3) vs 463±29 ms (LQT1). Interestingly, nearly half of the LQT1 patients (9/19) had a nondiagnostic resting QTc (<460 milliseconds), whereas 11 (41%) of 27 healthy controls had borderline prolongation (QTc >440 milliseconds) (Figure 2). No significant difference was noted in baseline heart rate between LQT1 (65±9 beats/min), LQT2/3 (61±8 beats/min), and controls (66±10 beats/min). The chronotropic response to epinephrine was similar between LQTS patients and controls, with the heart rate increasing by 19±15 beats/min in LQT1, 29±11 beats/min in LQT2/3, and 24±12 beats/min in controls (P=.06). In comparing only LQT1 and LQT2/3 patients, heart rate increased more during epinephrine infusion in LQT2/3 than in LQT1 patients (P=.02). Effect of on QTc lthough epinephrine tended to increase QTc in all 3 study groups (Figure 3, ), the epinephrine-mediated increase in QTc was significantly greater in LQT1 patients than in LQT2/3 patients and controls ( QTc [ QTc = epinephrine QTc minus baseline QTc], 143±52 ms [LQT1], 37±60 ms [LQT2/3], 65±46 ms [controls], Figure 3, ; P<.001). However, there was substantial overlap among the 3 groups such that the effect of epinephrine on Figure 3. Effect of epinephrine (Epi) on corrected QT interval (QTc) in patients with long QT syndrome (LQTS) and controls., The baseline QTc and the maximal QTc response regardless of Epi dose is displayed for each LQTS patient and control., The mean change in QTc ( QTc), SD, and individual QTc is displayed for the 3 study groups. The mean QTc was significantly greater in patients with LQT1 (P<.001), but overlap is considerable.
5 Mayo Clin Proc, May 2002, Vol 77 Infusion QT Stress Testing in LQTS 417 Figure 4. Effect of epinephrine on absolute QT interval in patients with long QT syndrome (LQTS)., Schematic of an epinephrine study in a patient with LQT1 showing the baseline and epinephrine traces from lead II. Note on the expanded time scale, an epinephrine QRST complex is superimposed on a baseline complex showing the paradoxical response of epinephrine-induced QT interval prolongation (arrow)., similar depiction is shown from a patient with a truncated C-terminal HERG mutation showing shortening of the QT interval with epinephrine. QTc failed to distinguish between the LQTS genotypes or even LQTS patients from controls. Effect of on the bsolute QT Interval The characteristic paradoxical response to epinephrine (ie, prolongation of the absolute QT interval) seen in every LQT1 patient regardless of their underlying KVLQT1 mutation is depicted in Figure 4,, and a typical epinephrinemediated QT shortening seen in LQT2/3 patients and also most controls is shown in Figure 4,. During epinephrine infusion, the absolute QT interval in LQT1 patients increased uniformly. In every LQT2/3 patient, the QT interval decreased uniformly. In controls, the QT interval response to epinephrine was not uniform (Figure 5, ). There was a marked difference between the mean change in QT ( QT [epinephrine QT minus baseline QT]) among the 3 study groups: +94±31 ms (LQT1), 87±67 ms (LQT2/3), and 5±47 ms (controls); P<.001 (Figure 5, ). Here, the change in QT was derived as the maximum difference obtained during the epinephrine infusion without respect to the dose at which the maximum response occurred. Thus, some patients manifested the greatest response during low-dose infusion (0.05 µg kg 1 min 1 ), whereas the greatest effect was observed in others during high-dose epinephrine infusion (0.3 µg kg 1 min 1 ). Patients with LQT1 and LQT2/3 were distinguished completely by the epinephrine-qt response (Figures 4 and 5). However, nearly half of the LQT1 patients were not discriminated from the controls with use of peak QT effect independent of epinephrine dose (Figure 5, ). Subset analysis of the QT response to only low-dose epinephrine (0.05 µg kg 1 min 1 ) showed a significantly greater response in LQT1 patients than in controls (+82±34 vs 7±13, Figure 6, ; P<.001). More importantly, there was no overlap between LQT1 patients and controls in the effect of low-dose epinephrine on the QT interval (Figure 6, ). lthough the subset analysis of the QT response to low-dose epinephrine demonstrated a significantly greater degree of QT interval shortening in LQT2/3 patients compared with controls, overlaps persisted between these 2 groups (data not shown). In contrast to this pathognomonic gene-specific paradoxical response to low-dose epinephrine, we could show no additive diagnostic utility during infusion of higher doses of epinephrine (0.2 and 0.3 µg kg 1 min 1 ). In fact, as shown in Figure 5,, high-dose epinephrine yielded a false-positive paradoxical response ( QT >30 milliseconds) in 6 (22%) of 27 controls. rrhythmogenicity and Safety of Challenge No LQTS patient or control required defibrillation. The study was discontinued before the entire epinephrine infusion protocol was completed in 11 LQTS patients (30%) because preset end point criteria were reached: 1 (LQT1) due to a 15-beat run of NSVT, 1 (LQT3) due to a 4-beat run of NSVT, 1 (LQT1) due to TW, 1 due to systemic hypertension, 1 due to an increasing number of PVCs, and 6 due to headache and nausea at the highest level of epinephrine infusion (0.3 µg kg 1 min 1 ). The epinephrine study of a 17-year-old female adolescent subsequently found to have a novel I235N-KVLQT1 missense mutation is depicted in Figure 7,. With low-dose epinephrine, the absolute QT interval lengthened from 450 milliseconds at baseline to 609 milliseconds. During infusion of 0.2 µg kg 1 min 1, an asymptomatic 15-beat run of VT occurred. Sinus
6 418 Infusion QT Stress Testing in LQTS Mayo Clin Proc, May 2002, Vol 77 Figure 5. Summary of the QT response to epinephrine (Epi) in patients with long QT syndrome (LQTS) and controls., The absolute QT interval is displayed on the y-axis for controls, LQT1 patients, and LQT2/3 patients at baseline and after Epi infusion. Note that the maximal effect (either lengthening or shortening) on the QT interval is shown regardless of the dose of Epi at which it occurred., The mean change in QT ( QT), SD, and individual QT is displayed for the 3 study groups. The mean QT was significantly greater in LQT1 patients (P<.001). The maximal QT response to Epi completely distinguishes LQT1 from LQT2/3 patients, but there is considerable overlap with healthy controls. rhythm recurred spontaneously, and the infusion was terminated. Striking macrovoltage TW that occurred during infusion of 0.2 µg kg 1 min 1 of epinephrine in a 37-yearold woman harboring a previously known splice-site mutation in KVLQT1 is shown in Figure 7,. mong the controls, 9 (33%) did not complete the entire epinephrine protocol because of bigeminy (2), an increasing number of PVCs (4), and headache/nausea (3). Of importance, there appeared to be no risk-stratifying value with the observation of epinephrine-induced ventricular ectopy in terms of increased frequency of single PVCs or bigeminy. One control (40-year-old woman) had a 3-beat run of NSVT during the highest dose of epinephrine (0.3 µg kg 1 min 1 ). Of 64 study participants, 61 (95%) tolerated the epinephrine infusion through 0.2 µg kg 1 min 1 without invoking any of the end point criteria. DISCUSSION Provocation and the I Ks Pathway: Molecular and Cellular Considerations KVLQT1 (chromosome 11p15.5) encodes the 676- amino acid α-subunit underlying one of the principal potas- Figure 6. QT prolongation with low-dose epinephrine (Epi) is pathognomonic for long QT syndrome subtype 1 (LQT1)., The QT response during low-dose Epi (0.05 µg kg 1 min 1 ) only is plotted on the y-axis for controls and LQT1 patients (KVLQT1). Change in QT interval ( QT) is displayed on the y-axis for controls and LQT1 patients., paradoxical response to low-dose Epi ( QT >30 milliseconds) now completely distinguishes LQT1 patients from controls (P<.001).
7 Mayo Clin Proc, May 2002, Vol 77 Infusion QT Stress Testing in LQTS 419 aseline (0.05 µg kg 1 min 1 ) (0.1 µg kg 1 min 1 ) (0.2 VT) aseline (0.05 µg kg 1 min 1 ) (0.1 µg kg 1 min 1 ) (0.2 VT) (0.2 VT) Recovery (5 min) Recovery (5 min) 200 ms 200 ms Figure 7. rrhythmogenicity during epinephrine provocation., -induced nonsustained ventricular tachycardia (VT). n epinephrine QT stress test from a 17-year-old female adolescent with a novel KVLQT1 missense mutation denoted I235N showing a paradoxical QT response to low-dose epinephrine (baseline, milliseconds) followed by a 15-beat run of nonsustained VT during administration of 0.2 µg kg 1 min 1 of epinephrine., -induced macrovoltage T-wave alternans (TW). n epinephrine QT stress test from a 37-year-old woman having a previously known splicing mutation denoted SP/344/g>a in KVLQT1. Once again, prolongation of the QT interval is evident ( milliseconds) during low-dose epinephrine. t 0.2 µg kg 1 min 1 of epinephrine, there is visible TW. In addition, the inverted P waves during epinephrine returned to a normal sinus P wave during the recovery period. sium channels (I Ks ) in the heart that is responsible for phase 3 repolarization. 2 The I Ks provides approximately 4 times the potassium current compared with the other predominant phase 3 repolarizing potassium current (I Kr encoded by HERG). The KVLQT1-encoded I Ks potassium channel is phosphorylated during sympathetic activation. Patients with LQTS who have KVLQT1 mutations are more prone to experience cardiac events under physically or mentally stressful situations and benefit the most from β-blocker therapy. 10,23 Sympathetic stimulation has more effects in patients with LQT1 than in patients with other types of LQTS and healthy individuals perturbation in the I Ks channel signaling complex could disrupt the balance of several currents, including I Ks, I Cl, and I Na-Ca, that are under sympathetic control and lead to failure of β-adrenergic stimulation to abbreviate the action potential duration and hence the QT interval in patients with LQT Mediated QT Prolongation: n In Vivo ssay for I Ks Perturbations Our data suggest that epinephrine provocation is indeed an in vivo functional assay capable of clinically evaluating the integrity of the I Ks channel signaling complex. 27 Every LQT1 patient, regardless of the underlying KVLQT1 channel mutation, displayed the paradoxical response of epinephrine-mediated QT interval prolongation, whereas LQTS patients with an intact I Ks pathway (ie, LQT2 and LQT3 patients) demonstrated shortening of the QT interval during epinephrine consistent with previous in vitro cellular mechanistic hypotheses. This strikingly divergent genotype-specific response explains why epinephrine challenges conducted in the decade preceding the molecular revelations in LQTS yielded such heterogeneous responses. 19 Moreover, the vast majority of putative KVLQT1 mutations have not been functionally characterized by site-directed mutagenesis molecular/cellular electrophysiologic studies. Thus far, we have observed this paradoxical response to epinephrine uniformly in LQT1 patients whether or not the patient had an N- terminal deletion, a missense mutation in the pore, or an illdefined splicing error (Figure 1). challenge testing may help provide objective evidence indicating whether a putative KVLQT1 mutation is functionally apparent in the whole organism (the patient) or perhaps simply an otherwise innocuous, dormant polymorphism. Provocation and Strategic LQTS Genotyping When a diagnostic QTc is present on the 12-lead ECG, the epinephrine challenge may foster strategic genotyping similar to the association of gene-specific arrhythmogenic triggers, like auditory stimuli in LQT2 and swimming in LQT1 patients If epinephrine-mediated QT prolongation is manifest, one should screen for KVLQT1 first. Indeed, this paradoxical response might be anticipated in patients with LQT5 because of a defect in the β-subunit (mink) of the I Ks channel. However, we have not yet con-
8 420 Infusion QT Stress Testing in LQTS Mayo Clin Proc, May 2002, Vol 77 ducted an epinephrine study on a known genotyped LQT5 patient to confirm this expectation. Nonetheless, LQT1 is at least 25 times more common than LQT5; thus, epinephrine-triggered prolongation can be considered pathognomonic for LQT1. In contrast, if there is epinephrine-mediated QT shortening (ie, a normal response to epinephrine), mutational analysis should begin with HERG unless other genotype-phenotype clues are present. Exposing Concealed LQTS With Use of The QT interval is a surface marker of cardiac electrical activity, specifically cellular repolarization. It is generally accepted that the absolute QT interval provides a surface rendering of the underlying cellular action potential durations. Despite overlap of the resting QTc between healthy persons and patients with LQTS, the 12-lead ECG remains one of the principal tools in the LQTS evaluation, and the baseline QTc is still one of the most important diagnostic criteria. 28 In our study, although the baseline QTc was significantly greater in LQTS patients than in controls, we found that 47% of genotyped LQT1 patients had a nondiagnostic resting QTc (<460 milliseconds), whereas 41% of healthy controls had borderline prolonged QTc (>440 milliseconds). In contrast, every LQT2/3 patient had a diagnostic resting QTc (>460 milliseconds). In this setting, the current gold standard clinical test, the 12-lead ECG, failed to distinguish nearly half of the LQT1 patients and controls. Perhaps more important than facilitating strategic genotyping, the epinephrine challenge may allow one to unmask patients harboring concealed LQT1. lthough some controls showed significant paradoxical QT prolongation at higher doses of epinephrine, low-dose epinephrine (0.05 µg kg 1 min 1 ) completely discriminated LQT1 patients from controls. It is possible that the QT prolongation seen at higher doses of epinephrine in controls was secondary to epinephrine-mediated hypokalemia, as previously shown. 21 However, we did not determine serum potassium levels in this study. Thus, the epinephrine challenge may be of diagnostic value in the clinical evaluation of unexplained syncope or sudden death in which there is a clinical index of suspicion for LQTS but a nondiagnostic ECG. Indeed, we have demonstrated how this epinephrine challenge revealed concealed LQT1 in the mother of a 17-year-old female adolescent found dead in bed and fostered a successful molecular autopsy confirming a KVLQT1 mutation in the deceased person. 20 rrhythmogenicity and Safety of Provocation studies can be conducted safely in patients with LQTS. None of our LQTS patients or controls required defibrillation. Only 1 of the 37 LQTS patients had a prolonged episode of NSVT. ecause epinephrine-induced polymorphic VT or ventricular fibrillation remains a theoretical concern, we continue to connect patients to a bedside cardioverter-defibrillator system at the start of each epinephrine challenge. Importantly, infusion of epinephrine does not appear to have a role in risk stratification. induced PVCs were observed as commonly in controls as in LQTS patients, and their presence does not indicate clinical risk. ecause no diagnostic information was apparent at the highest dose of epinephrine (0.3 µg kg 1 min 1 ), we have discontinued this dose, and our current maximum infusion is 0.2 µg kg 1 min 1. In this study, more than 95% of the LQTS patients and controls would have completed the entire protocol without adverse effects, complications, or reaching end point criteria with this revised ceiling dose. Study Limitations This study has 3 main limitations. First, it was not blinded. The principal investigator (M.J..) who measured the various parameters of repolarization knew which study participants were controls and which had clinical LQTS at the start of the epinephrine provocation. However, another investigator (J..H.) independently confirmed the QT measurements in each study and was blinded to the patient s underlying genotype. Moreover, nearly half of the LQTS patients were not successfully genotyped until several months after the epinephrine study. In fact, the genotype of 8 of the 19 LQT1 patients was unknown at the time of the study. Thus, it is most unlikely that bias was introduced because of the unblinded study design. Second, only 3 LQT3 patients, from the same family harboring obviously the same sodium channel mutation, were studied, and each LQT3 patient had shortening of their QT interval during epinephrine infusion similar to the LQT2 patients. However, it remains to be shown whether epinephrine-induced QT shortening is universal for LQT3 patients. In addition, our LQTS cohort contained no LQT2 patient with an equivocal, nondiagnostic resting QTc. Whether the apparent accentuated shortening of the QT interval with epinephrine seen in the genotyped LQT2 patients compared with controls could be used to unmask concealed LQT2 remains to be shown. Finally and most importantly, this epinephrine study was conducted in the absence of the potential confounding effect of β-blocker therapy, except for 2 patients (both LQT2) who were taking β-blockers at the time of the study. The remaining LQTS patients were not taking β-blockers because of initial clinical evaluation, elective noncompliance, implantable cardioverter-defibrillator as monotherapy, or 48-hour washout of β-blocker. Thus, we do not know whether β- blockers would obscure the observed genotype-specific re-
9 Mayo Clin Proc, May 2002, Vol 77 Infusion QT Stress Testing in LQTS 421 sponse to epinephrine or the ability to unmask an LQT1 patient with an equivocal QTc at rest. We urge caution in attempting to generalize these findings to the patient taking β-blockers at the time of study and recommend admission to the hospital for monitored β-blocker washout if this test is deemed appropriate for clinical evaluation. CONCLUSIONS There appears to be an essential role for epinephrine infusion QT stress testing in evaluating LQTS and unexplained sudden cardiac death. The previous disparate responses to epinephrine are now understood in light of the profound molecular heterogeneity underlying LQTS. In addition, the diagnostic superiority of epinephrine-mediated changes in QT interval rather than the effect on QTc are clearly evident. Provocation with epinephrine may provide an in vivo functional assay to interrogate putative KVLQT1 mutations. Of the 5 known LQTS genotypes, the paradoxical response involving prolongation of the absolute QT interval with low-dose epinephrine appears pathognomonic for LQT1 and can be used to direct genotyping efforts and to unmask LQT1 patients who have concealed LQTS. We thank the controls who volunteered for this study and the patients with LQTS and their families for joining together to heal the sick and to advance the science [Charles H. Mayo, MD]. REFERENCES 1. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104: ckerman MJ, Clapham DE. Ion channels basic science and clinical disease [published correction appears in N Engl J Med. 1997;337:579]. N Engl J Med. 1997;336: ckerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998;73: Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12: Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80: ennett P, Yazawa K, Makita N, George L Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376: Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q m J Hum Genet. 1995;57: Sanguinetti MC, Curran ME, Zou, et al. Coassembly of K(V)LQT1 and mink (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996;384: Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-qt syndrome genes: KVLQT1, HERG, SCN5, KCNE1, and KCNE2. Circulation. 2000;102: Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-qt syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103: Moss J, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. m J Cardiol. 1999;84: ckerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc. 1999;74: Miller MD, Porter C, ckerman MJ. Diagnostic accuracy of screening electrocardiograms in long QT syndrome I. Pediatrics. 2001;108: Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long- QT syndrome. N Engl J Med. 1992;327: Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-qt syndrome: clinical impact. Circulation. 1999;99: Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. m J Cardiol. 1991;68: Schwartz PJ, Vanoli E, Stramba-adiale M, De Ferrari GM, illman GE, Foreman RD. utonomic mechanisms and sudden death: new insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78: Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J m Coll Cardiol. 1999;34: Jackman WM, Friday KJ, nderson JL, liot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31: Shimizu W, Ohe T, Kurita T, Tokuda T, Shimomura K. -induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome. J Cardiovasc Electrophysiol. 1994;5: ckerman MJ, Tester DJ, Driscoll DJ. Molecular autopsy of sudden unexplained death in the young. m J Forensic Med Pathol. 2001;22: Darbar D, Smith M, Morike K, Roden DM. -induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. m J Cardiol. 1996;77: Moss J, Zareba W, Hall WJ, et al. Effectiveness and limitations of β-blocker therapy in congenital long-qt syndrome. Circulation. 2000;101: Shimizu W, ntzelevitch C. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. J Electrocardiol. 1999;32(suppl): Shimizu W, ntzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J m Coll Cardiol. 2000;35: Shimizu W, ntzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-qt syndrome: effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 1998;98: Marx SO, Kurokawa J, Reiken S, et al. Requirement of a macromolecular signaling complex for β adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science. 2002;295: Schwartz PJ, Moss J, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993; 88:
Diagnostic Scoring System for LQTS
Medical Coverage Policy Genetic Testing: Congenital Long QT Syndrome Device/Equipment Drug Medical Surgery Test Other Effective Date: 2/15/2011 Policy Last Updated: 2/21/2012 Prospective review is recommended/required.
More informationUsefulness of Epinephrine Test in the Congenital Long QT Syndrome
Usefulness of Epinephrine Test in the Congenital Long QT Syndrome Wataru Shimizu M.D., Ph.D. CASE PRESENTATION A 14-year old Japanese boy was successfully resuscitated from cardiac arrest (near drowning)
More informationJanuary 14-15, 2011 SCA Conference 2
Electrical Abnormalities: Long QT and Beyond Yaniv Bar-Cohen, M.D. Assistant Professor of Pediatrics Division of Cardiology / Electrophysiology Childrens Hospital Los Angeles Keck School of Medicine Genetic
More informationA Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated by Mexiletine: The Role of Epinephrine Provocation Test
Case Report http://dx.doi.org/10.3349/ymj.2013.54.2.529 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(2):529-533, 2013 A Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated
More informationLife Threatening EKG s In The Office. Joseph A Manfredi, MD, FACC, FHRS GHS Cardiovascular Symposium
Life Threatening EKG s In The Office Joseph A Manfredi, MD, FACC, FHRS GHS Cardiovascular Symposium January 24 th, 2015 Disclosures Speaker Honorariums: STJM, Boston Scientific Advisory role: Medtronic
More informationLong QT. Long QT Syndrome. A Guide for
Long QT Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United
More informationGenetic Long QT Syndrome GENETIC TESTING FOR LONG QT SYNDROME HS-148. Policy Number: HS-148. Original Effective Date: 1/21/2010
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationElectrocardiographic Issues in Williams Syndrome
Electrocardiographic Issues in Williams Syndrome R. Thomas Collins II, MD Assistant Professor, Pediatrics and Internal Medicine University of Arkansas for Medical Sciences Arkansas Children s Hospital
More informationLong QT syndrome! Should we treat all asymptomatic patients?!
! Long QT syndrome! Should we treat all asymptomatic patients?! Venice Arrhythmia 2015! Arthur A.M. Wilde Heart Centre NO CONFLICT OF INTEREST TO DECLARE Long QT Syndrome(s) Autosomal dominant/autosomal
More informationAcquired, Drug-Induced Long QT Syndrome
Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP
More informationApplication for a Marketing Authorisation: Requirements and Criteria for the Assessment of QT Prolonging Potential
Application for a Marketing Authorisation: Requirements and Criteria for the Assessment of QT Prolonging Potential Bundesinstitut für Arzneimittel Dr. med. Clemens Mittmann Bundesinstitut für Arzneimittel
More informationRole of implantable cardioverter defibrillator therapy in patients with long QT syndrome
Role of implantable cardioverter defibrillator therapy in patients with long QT syndrome James P. Daubert, MD, Wojciech Zareba, MD, PhD, Spencer Z. Rosero, MD, Adam Budzikowski, MD, PhD, Jennifer L. Robinson,
More informationThe long-qt syndrome (LQTS) is an inherited or acquired
Compound Mutations A Common Cause of Severe Long-QT Syndrome Peter Westenskow, BS; Igor Splawski, PhD; Katherine W. Timothy, BS; Mark T. Keating, MD; Michael C. Sanguinetti, PhD Background Long QT syndrome
More informationGuidelines for the diagnosis and management of Familial Long QT Syndrome
The Cardiac Society of Australia and New Zealand Guidelines for the diagnosis and management of Familial Long QT Syndrome These guidelines were revised by Dr Jonathan Skinner and a members of the Cardiovascular
More informationPreviously Published Works UC San Francisco
Previously Published Works UC San Francisco A University of California author or department has made this article openly available. Thanks to the Academic Senate s Open Access Policy, a great many UC-authored
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Cardiac Ion Channelopathies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_cardiac_ion_channelopathies 10/2008 4/2015
More informationCongenital long QT syndrome: Considerations for primary care physicians
REVIEW CME CREDIT ETHAN LEVINE, DO Cardiology Division, Department of Medicine, University of Rochester Medical Center, Rochester, NY ARTHUR J. MOSS, MD Cardiology Division, Department of Medicine, University
More informationThe QT interval: Too long, too short or just right
CONTEMPORARY REVIEW The QT interval: Too long, too short or just right Sami Viskin, MD From Tel-Aviv Sourasky Medical Center, Sackler-School of Medicine, Tel Aviv, Israel. The hallmark of the congenital
More informationSudden Arrhythmia Death Syndrome: Importance of the Long QT Syndrome
Sudden Arrhythmia Death Syndrome: Importance of the Long QT Syndrome JOHN S. MEYER, M.D., St. Luke s Hospital, Chesterfield, Missouri ALI MEHDIRAD, M.D., Midwest Heart Rhythm, St. Louis, Missouri BAKR
More informationInvestigation of Ion Channel Gene Variants in Patients with Long QT Syndrome
Investigation of Ion Channel Gene Variants in Patients with Long QT Syndrome Ernesto Curty 1, Fernando Eugênio dos Santos Cruz 2, Fabiane Santos Lima 1, Jorge Luiz Albuquerque Coutinho 2, Rosane Silva
More informationLong-QT Syndrome. The Cl inic a l Problem
T h e n e w e ng l a nd j o u r na l o f m e dic i n e clinical practice Long-QT Syndrome Dan M. Roden, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence
More informationREVIEW ARTICLES BACKGROUND
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00716-6 REVIEW
More informationOverview of Inherited Heart Rhythm Disorders for Patients
Introduction Overview of Inherited Heart Rhythm Disorders for Patients Inherited heart rhythm disorders affect a small portion of the population, presenting as palpitations, fainting, heart arrest and
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationMedical Policy Manual. Topic: Genetic Testing for Cardiac Ion Channelopathies Date of Origin: December 2012
Medical Policy Manual Topic: Genetic Testing for Cardiac Ion Channelopathies Date of Origin: December 2012 Section: Genetic Testing Last Reviewed Date: December 2015 Policy No: 07 Effective Date: January
More informationLong QT syndrome: from channels to cardiac arrhythmias
Review series Long QT syndrome: from channels to cardiac arrhythmias Arthur J. Moss 1 and Robert S. Kass 2 1 Heart Research Follow-up Program, Department of Medicine, University of Rochester School of
More informationNEONATAL & PEDIATRIC ECG BASICS RHYTHM INTERPRETATION
NEONATAL & PEDIATRIC ECG BASICS & RHYTHM INTERPRETATION VIKAS KOHLI MD FAAP FACC SENIOR CONSULATANT PEDIATRIC CARDIOLOGY APOLLO HOSPITAL MOB: 9891362233 ECG FAX LINE: 011-26941746 THE BASICS: GRAPH PAPER
More informationHIV, High Dose Methadone, and the Treatment Conundrum 5/8/2014. Frederick L. Altice, MD, MA
EXPERT PANEL Managing HIV in Special Circumstances: Patients on High-Dose Methadone Frederick L. Altice, MD, MA Professor of Medicine, Epidemiology, and Public Health Yale University HIV, High Dose Methadone,
More informationClinical Perspective. Molecular genetics of inherited long QT syndromes. The long QT syndrome. Introduction. Clinical aspects/diagnostic criteria
European Heart Journal (1998) 19, 1427 1433 Article No. hj980873 Clinical Perspective Molecular genetics of inherited long QT syndromes Introduction Unravelling the molecular cause of QT prolongation is
More informationProvocative testing with epinephrine infusion has become
Epinephrine Infusion in the Evaluation of Unexplained Cardiac Arrest and Familial Sudden Death From the Cardiac Arrest Survivors With Preserved Ejection Fraction Registry Andrew D. Krahn, MD; Jeffrey S.
More informationL ong QT syndrome causes sudden
LEADING ARTICLE 445 Cardiology... Is there a relation between SIDS and long QT syndrome? J R Skinner... A discussion of the evidence to date L ong QT syndrome causes sudden unexpected death through rapid
More informationsudden cardiac death, torsades de pointes, T wave alternans, syncope, genetic mutation
Reprinted with permission from JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY Volume 12 No. 4 April 2001 Copyright 2001 by Futura Publishing Company Inc. Armonk NY 10504-0418 Electrocardiographic Prediction
More informationLQTS: Long QT Syndrome. Inherited Heart Disease Clinic
2011 LQTS: Long QT Syndrome Inherited Heart Disease Clinic What is LQTS? LQTS is a rare heart rhythm disorder. It causes a disruption of the electrical signal that stimulates your heart to beat. It occurs
More informationThe Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate
More informationNovartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)
Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
More informationOver the past decade, the discovery of mutations in
Review Novel Insights in the Congenital Long QT Syndrome Xander H.T. Wehrens, MD; Marc A. Vos, PhD; Pieter A. Doevendans, MD; and Hein J.J. Wellens, MD Background: The congenital long QT syndrome is a
More informationRisk Stratification in the Long-QT Syndrome
The new england journal of medicine original article Risk Stratification in the Long-QT Syndrome Silvia G. Priori, M.D., Ph.D., Peter J. Schwartz, M.D., Carlo Napolitano, M.D., Ph.D., Raffaella Bloise,
More informationGenetic Testing for Long QT Syndrome
Technology Evaluation Center Genetic Testing for Long QT Syndrome Assessment Program Volume 22, No. 9 February 2008 Executive Summary Background A genetic test is currently commercially available for mutations
More informationDental treatment of a patient with long QT syndrome under moderate sedation with target-controlled infusion of propofol
Case Report pissn 2383-9309 eissn 2383-9317 J Dent Anesth Pain Med 2015;15(3):161-165 http://dx.doi.org/10.17245/jdapm.2015.15.3.161 Dental treatment of a patient with long QT syndrome under moderate sedation
More informationAssessment, diagnosis and specialist referral of adults (>16 years) with an episode of transient loss of consciousness (TLoC) or a blackout.
Assessment, diagnosis and specialist referral of adults (>16 years) with an episode of transient loss of consciousness (TLoC) or a blackout. TLoC is common huge variation in management range of clinicians
More informationLong-QT syndrome (LQTS) is a cardiovascular disorder
Spectrum of Mutations in Long-QT Syndrome Genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Igor Splawski, PhD; Jiaxiang Shen, MS; Katherine W. Timothy, BS; Michael H. Lehmann, MD; Silvia Priori, MD, PhD; Jennifer
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationBy Theresa A. Beery, RN, PhD, ACNP, Kerry A. Shooner, MS, CGC, and D. Woodrow Benson, MD, PhD
Cases of Note Cases of Note features peer-reviewed case reports and case series that document clinically relevant findings from critical and high acuity care environments. Cases that illuminate clinical
More informationPotential Causes of Sudden Cardiac Arrest in Children
Potential Causes of Sudden Cardiac Arrest in Children Project S.A.V.E. When sudden death occurs in children, adolescents and younger adults, heart abnormalities are likely causes. These conditions are
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S7B
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE NON-CLINICAL EVALUATION OF THE POTENTIAL FOR
More informationHow to read the ECG in athletes: distinguishing normal form abnormal
How to read the ECG in athletes: distinguishing normal form abnormal Antonio Pelliccia, MD Institute of Sport Medicine and Science www.antoniopelliccia.it Cardiac adaptations to Rowing Vagotonia Sinus
More informationWhat Does It Mean to have a Gene?
CHAPTER 25 What Does It Mean to have a Gene? by Walter Allan, M.D. More than a year after we had sent the blood samples on Kara, Guerin, Tom and Maryann to Dr. Mark Keating s lab in Salt Lake City we still
More informationHow to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
More informationEquine Cardiovascular Disease
Equine Cardiovascular Disease 3 rd most common cause of poor performance in athletic horses (after musculoskeletal and respiratory) Cardiac abnormalities are rare Clinical Signs: Poor performance/exercise
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationLong QT Syndrome: A Pamphlet for Community Awareness in Prevention of Sudden Cardiac Death in the Young
Long QT Syndrome: A Pamphlet for Community Awareness in Prevention of Sudden Cardiac Death in the Young Bauke Pier Lettenga Helena Lustig Bachelor s Thesis November 2009 School of Health and Social Studies
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Genetic Testing for Long QT Syndrome NMP490 Effective Date*: February 2005 Updated: August 2015 This National Medical Policy is subject to the terms in the
More informationGuidance for Industry
Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs U.S. Department of Health and Human Services Food and Drug Administration
More informationAtrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated
More informationLAST NAME VAT NUMBER. PHONE (Important for possible case discussion)
Long QT Panel CUSTOMER INFORMATION FIRST NAME LAST NAME ORGANIZATION VAT NUMBER BILLING ADDRESS 1ST LINE BILLING ADDRESS 2ND LINE POST CODE CITY COUNTRY EMAIL (Required) PHONE (Important for possible case
More informationIntroduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center
Introduction to Electrophysiology Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center Objectives Indications for EP Study How do we do the study Normal recordings Abnormal Recordings Limitations
More informationQT analysis: A guide for statistical programmers. Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012
QT analysis: A guide for statistical programmers Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012 Agenda ECG ICH E14 Thorough QT/QTc study Role of Statistical Programmer References
More informationPharmacology & Therapeutics
Pharmacology & Therapeutics 131 (2011) 171 177 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: O. Binah Pharmacological
More informationGenetic Testing in the Long QT Syndrome
ORIGINAL CONTRIBUTION Genetic Testing in the Long QT Syndrome Development and Validation of an Efficient Approach to Genotyping in Clinical Practice Carlo Napolitano, MD, PhD Silvia G. Priori, MD, PhD
More informationDepressive symptoms in the congenital long QT syndrome
Annals of Medicine. 2009; 41: 516521 ORIGINAL ARTICLE Depressive symptoms in the congenital long QT syndrome TAINA HINTSA 1, LIISA KELTIKANGAS-JÄRVINEN 1, SAMPSA PUTTONEN 2, NIKLAS RAVAJA 3, LAURI TOIVONEN
More informationSudden unexplained death in infancy and long QT syndrome. Jonathan Robert Skinner
Sudden unexplained death in infancy and long QT syndrome. Jonathan Robert Skinner Greenlane Paediatric and Congenital Cardiac Services, Starship Children s Hospital, Park Road, Grafton, Auckland New Zealand.
More informationIntroduction. What is syncope?
Syncope Introduction What is syncope? Syncope (SING-kuh-pee) is a medical term for fainting. When you faint, your brain is not receiving enough blood and oxygen, so you lose consciousness temporarily.
More informationLong QT Syndrome Genetic Testing for Inherited Arrhythmias. patient guide
Long QT Syndrome Genetic Testing for Inherited Arrhythmias patient guide What is Long QT Syndrome? Arrhythmias are problems with the electrical system in the heart that controls the heartbeat s regular
More informationRecurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
More informationCardiopatie Aritmogene nel Giovane
Firenze, 16 Novembre 2012 Cardiopatie Aritmogene nel Giovane Prof. Luigi Padeletti Università degli Studi di Firenze 1) Long QT Syndrome 2) Short QT Syndrome 3) J wave Syndrome: Early Repolarization Syndrome
More informationINTRODUCTORY GUIDE TO IDENTIFYING ECG IRREGULARITIES
INTRODUCTORY GUIDE TO IDENTIFYING ECG IRREGULARITIES NOTICE: This is an introductory guide for a user to understand basic ECG tracings and parameters. The guide will allow user to identify some of the
More informationDanish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen
Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen PhD course: Cardiac arrhythmias - Aim and content: Cardiac arrhythmia represents a wide spectrum of abnormalities
More informationMutation-Specific Pharmacology of the Long QT Syndrome
HEP (2006) 171:287 304 Springer-Verlag Berlin Heidelberg 2006 Mutation-Specific Pharmacology of the Long QT Syndrome R.S. Kass 1 ( ) A.J.Moss 2 1 Department of Pharmacology, Columbia University College
More informationARTICLE IN PRESS. Available online at www.sciencedirect.com. Received 5 November 2008
Available online at www.sciencedirect.com Journal of Electrocardiology xx (2009) xxx xxx www.jecgonline.com Exploring QT interval changes as a precursor to the onset of ventricular fibrillation/tachycardia
More informationApplication of a Computerized Medical Decision-Making Process to the Problem of Digoxin Intoxication
JACC Vel 4, No.3 Septernbe 1984:571-6 571 Application of a Computerized Medical Decision-Making Process to the Problem of Digoxin Intoxication KEITH S. WHITE, ALAN LINDSAY, MD, FACC, T. ALLAN PRYOR, PHD,
More informationElectrocardiography Review and the Normal EKG Response to Exercise
Electrocardiography Review and the Normal EKG Response to Exercise Cardiac Anatomy Electrical Pathways in the Heart Which valves are the a-v valves? Closure of the a-v valves is associated with which heart
More informationNew Study Questions Sports Restrictions for Children with Long QT Syndrome
(http://consultqd.clevelandclinic.org) RESEARCH Apr. 22, 2015 @ 9:31 a.m. New Study Questions Sports Restrictions for Children with Long QT Syndrome A wider range of activities may be safe Conventional
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationGUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS. (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support)
AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support) The term cardiac arrhythmia
More informationElectrolyte Physiology. Something in the way she moves
Electrolyte Physiology Something in the way she moves me Electrolyte Movement CONCENTRATION GRADIENT ELECTRICAL GRADIENT DRIVING FORCE NERNST NUMBER (E-ion) CONDUCTANCE (G-ion) PERMEABILITY CHANNELS: small
More informationTitle The Mental Health of Adolescents Living with Potentially Fatal Arrhythmia: A Systematic Review of the Literature
PROSPERO Registration of Systematic Review Title The Mental Health of Adolescents Living with Potentially Fatal Arrhythmia: A Systematic Review of the Literature Registration - - - to be registered in
More informationGenetic Predisposition to Ventricular Arrhythmias and. Sudden Death in Hypertrophic Cardiomyopathy
Dott.ssa Daria Santini Dottorato di Ricerca in Medicina Sperimentale Genetic Predisposition to Ventricular Arrhythmias and Sudden Death in Hypertrophic Cardiomyopathy Background Hypertrophic cardiomyopathy
More informationThe Long-QT Syndrome: A Silent Killer
The Long-QT Syndrome: A Silent Killer Claire Crowley CLINICAL POINTS The long-qt syndrome can be inherited or acquired. It affects the function of cardiac ion channels and is characterised by a prolonged
More informationThe functional characterisation of
Review Article Hellenic J Cardiol 2012; 53: 439-446 Effects of Mutations and Genetic Overlap in Inherited Long-QT and Brugada Arrhythmia Syndromes Christina-Maria Kotta, Aris Anastasakis, Christodoulos
More informationGenetics of sudden death
Review Article Indian J Med Res 132, November 2010, pp 579-583 Genetics of sudden death Nitish Naik & Rakesh Yadav Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India Received
More informationInnovation Platform: Sudden Cardiac Death
Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration
More informationVENTRICULAR ARRHYTHMIAS
Page 1 of 20 Cardiology Clinics Volume 18 Number 2 May 2000 Copyright 2000 W. B. Saunders Company VENTRICULAR ARRHYTHMIAS LONG QT SYNDROME G. Michael Vincent MD Department of Internal Medicine, LDS Hospital;
More informationwww.irishheart.ie LONG QT SYNDROME SUPPORT GROUP IRELAND
www.irishheart.ie LONG QT SYNDROME SUPPORT GROUP IRELAND Long QT Syndrome Support Group This is a voluntary group of people, all of whom have families with Long QT syndrome (LQTS). It was set up in association
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationAtrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationDUKE EP SYMPOSIUM. Long QT Syndrome: Genotype- Phenotype Correlations
DUKE EP SYMPOSIUM Long QT Syndrome: Genotype- Phenotype Correlations Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Med Center Rochester, NY Cary, NC January 21, 2011 CONFLICT
More informationAdding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT
Adding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT Introduction Before the year 2000, the traditional antiarrhythmic agents (lidocaine, bretylium, magnesium sulfate, procainamide,
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationCurrent Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose
Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.
More informationIl loop recorder esterno. Roberto Maggi
Il loop recorder esterno Roberto Maggi ECG monitoring and syncope In-hospital monitoring Holter Monitoring Event recorder External loop recorder Remote (at home) telemetry Implantable loop recorder External
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationMEDICAL POLICY. 03/17/16 CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationSignal-averaged electrocardiography late potentials
SIGNAL AVERAGED ECG INTRODUCTION Signal-averaged electrocardiography (SAECG) is a special electrocardiographic technique, in which multiple electric signals from the heart are averaged to remove interference
More information1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA
1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate
More informationCrash Cart Drugs Drugs used in CPR. Dr. Layla Borham Professor of Clinical Pharmacology Umm Al Qura University
Crash Cart Drugs Drugs used in CPR Dr. Layla Borham Professor of Clinical Pharmacology Umm Al Qura University Introduction A list of the drugs kept in the crash carts. This list has been approved by the
More informationAutomatic External Defibrillators
Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationEffect of mexiletine on long QT syndrome model 1
316 2003, Acta Pharmacologica Sinica Chinese Pharmacological Society Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com Effect of mexiletine on long QT syndrome model
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More information